New anti-obesity pills threaten Eli Lilly and Novo Nordisk’s stock market empire​

​

New pills to combat obesity are threatening Eli Lilly and Novo Nordisk on the stock market. The two pharmaceutical companies are the dominant players in the weight loss market, since (for the time being) they are the only ones producing and marketing anti-obesity drugs. However, this is a very greedy business and in recent months other laboratories, attracted by this millionaire empire, have made progress with their own drugs, arousing the interest of the market and sparking doubts about the empire of the two giants, which have seen shares fall.

Seguir leyendo

  Ozempic, Novo Nordisk, Roche, Pfizer, Eli Lilly  Leer más